Jan 15, 2020 / 09:00PM GMT
Xiao Yu Li - JP Morgan Chase & Co, Research Division - Analyst
Okay. Good afternoon, everyone. I'm David Li from JPMorgan Equity Research. Now it's my pleasure to introduce Mr. Hogg, the CEO of Hutchison China MediTech. Thank you.
Christian Hogg - Hutchison China MediTech Limited - CEO & Executive Director
Thank you, David. Okay. So we've got 25 minutes. I'm going to take everybody through a brief summary of our business and the current status and the outlook for the year. So on a high level, what is Hutchison China MediTech trying to achieve? We're obviously a China-based biotech that is endeavoring to become a global biotech. We have developed -- discovered and developed a range of small molecule targeted therapies, all of which have been designed for the global market. But obviously, with our location in China, and that being our home market, our first step is to maximize the potential in China. But we are very much focused on becoming a global based -- a global science-focused biotech based in China.
So looking at our operations, it sort of
Hutchison China MediTech Ltd at JPMorgan Healthcare Conference Transcript
Mar 04, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers